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ABSTRACT 
Myocardial infarction (MI) is the leading cause of death worldwide causing irreversible 
damage to the heart. Despite the incidence and prevalence of MI, current treatments delay the 
progression of the damage rather than regenerate the function of the cardiac tissue. Over the past 
years, there has been a rising interest in cardiac tissue engineering, and three-dimensional (3D) 
bioprinting, to design regenerative approaches to treat damage to the heart caused by MI. 
Particularly, bioengineered cardiac patches have shown their potential in restoring cardiac tissue 
structure and function. Regardless of this progress, the clinical application of current cardiac tissue 
engineering platforms remains limited by shortcomings, ranging from poor vascularization to 
reduced cellular survival. This study investigated the fabrication of perfusable 3D bioprinted 
cardiac patches with functional vascular networks. Cardiac patch devices were 3D bioprinted with 
gelatin methacrylate (gelMA) hydrogel with channels bioprinted using a sacrificial pluronic 
bioink. The cardiac constructs were seeded with human umbilical vein endothelial cells (HUVECs) 
and cultured in static, dynamic, and perfusion conditions throughout a two-week period to evaluate 
in vitro the cellular growth and organization within the channels. The results from this study 
suggested that the 3D model of the patch was successfully bioprinted with the formation of fully 
patent and endothelialized channels. Although no significant differences were found in cellular 
metabolic activity between static and dynamic conditions at all timepoints, perfused cardiac 
patches showed a decrease in cellular metabolic activity at day 10 and day 14. Furthermore, 
qualitative results indicated the successful attachment of HUVECs on the channel walls. Overall, 
these results suggest that the developed cardiac patch devices serve as a potential model to repair 
and restore in vitro cardiac tissue after MI. In addition, novel 3D bioprinted vascularized cardiac 
  xi 
constructs can be used as research enabling an in vitro platform to provide insights into cardiac 
tissue homeostasis, diseases, and therapies.  
  1 
CHAPTER 1 
INTRODUCTION 
Heart failure (HF) due to myocardial infarction (MI) is the leading cause of morbidity and 
mortality worldwide affecting over 700,000 people per year [1-3]. MI can be attributed to multiple 
causes, such as mechanical valve complications, comorbidities as hypertension, malignant 
arrythmias, among others, which cause a local hypoxia in the myocardium. Eventually, continued 
ischemia in the myocardium causes the loss of cardiomyocytes. However, the limited capability 
for post-natal proliferation of cardiomyocytes as terminally differentiated cells results in 
diminished cardiac function, dilatation of the cardiac chambers, and thinning of the chamber walls 
following the ischemic injury [4, 5]. Ultimately, these processes lead to overall irreversible cardiac 
dysfunction, terminating in HF. 
 
Currently, heart transplantation remains the main treatment for end-stage HF [6]. Nonetheless, 
heart transplants remain highly invasive as the transplanted heart can be rejected by cellular and 
antibody mediated responses. Most impactfully, heart transplantations are restricted by the reduced 
number of heart donors [1]. Although other treatments, such as ventricular assist devices, cellular 
cardiomyoplasties, and immunotherapies have been implemented to repair cardiac tissue post-MI, 
their main objective is to palliate symptoms and delay the progression of HF rather than counteract 
the loss of functional tissue [4, 7]. Despite promising results, cardiac engineering continues to 
advance to target therapeutics for tissue repair after irreversible damage to the heart.  
 
In recent years, tissue engineering and, in particular, three-dimensional (3D) bioprinting have 
evolved as alternative means to design tissue constructs, used as cardiac patches, with remarkable 
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regenerative properties. Engineering cardiac patch devices that can repair heart tissue has been of 
great interest as a potential therapy in promoting cardiomyocyte regeneration and restoring cardiac 
functions [8]. Predominantly, 3D bioprinting has emerged as a technique to generate scaffold 
systems by controlling the geometry of constructs while designing customizable and reproducible 
structures for tissue regeneration applications [9, 10]. However, recent advances in tissue 
engineered patch devices remain limited by the insufficiency in their biocompatibility, functional 
vascularization, reproducibility, and cell survival and functionality characteristics.  
 
To address these issues, this work aims to develop and evaluate in vitro an engineered 
vascularized patch model for cardiac tissue regeneration addressing the challenges in MI 
treatments to date. We investigate the fabrication of 3D bioprinted cardiac patch devices with 
perfusable vasculature, which can promote regeneration of damaged myocardium after MI. To this 
end, the cardiac constructs are bioprinted with gelatin methacrylate (gelMA) hydrogel, while a 
sacrificial pluronic bioink is used to print an interconnected vascular channel network within the 
3D construct. To evaluate the function of the bioprinted patches, the constructs are endothelialized 
with human umbilical vein endothelial cells (HUVECs) and subjected to cell culturing throughout 
a two-week time period in static, dynamic (rocking), or perfusion culture conditions.  
 
We hypothesize that the geometry and biomaterials of the 3D bioprinted cardiac patch 
systems, consisting of gelMA hydrogel and sacrificial pluronic bioink, support the attachment, 
growth, and metabolism of HUVECs and, therefore, can be used to create endothelialized 
perfusable microvessels in the bioprinted devices. In addition, as gelMA has been gaining 
increasing attention over the past decade for its biological cues and shape integrity, we hypothesize 
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that the use of gelMA in bioprinting contributes to the formation of biocompatible cardiac patch 
systems with high structural fidelity and survival of HUVECs within the pre-engineered channels 
[11, 12]. Furthermore, the printability of sacrificial pluronic as a bioink has motivated its use in 
3D bioprinting. Once degraded at low temperatures, we hypothesize that the printed pluronic 
allows the formation of microchannels intrinsic to the bioprinted cardiac patches. With respect to 
the culture conditions, a significant difference in cellular growth among static, dynamic, and 
perfusion is hypothesized. Particularly, an increase in HUVEC metabolic activity is predicted for 
the perfused cardiac constructs.  
 
Here, we demonstrated that the 3D model was successfully bioprinted with gelMA hydrogel 
and pluronic bioink with the formation of fully patent channels. Furthermore, results showed that 
the seeded HUVECs had significant attachment, proliferation, and formed a smooth, uniform, and 
relatively mature endothelium in the vascular networks. However, no significant differences in 
cellular metabolic activity and proliferation were observed between the static and dynamic culture 
throughout the 14-day period suggesting that these conditions do not provide a significant 
difference in optimal environments for cell growth and endothelialization. However, the perfused 
cardiac patches showed a significant decrease in cellular metabolic activity beginning at day 7 
compared to static and rocking groups. These could be attributed to possible HUVEC detachment 
and loss as a result of built-up wall shear stress in the perfused channels, suggesting that further 
optimization would be required to design more robust in vitro perfusion systems. In general, we 
evaluated in vitro the geometry and culture conditions required to design 3D bioprinted patches 
for cardiac tissue regeneration providing an alternative strategy to engineer patch devices that are 
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highly reproducible, biocompatible, and with functional endothelialization of the pre-formed 
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CHAPTER 2 
LITERATURE REVIEW 
In recent years, there has been a heightened emphasis towards developing regenerative 
technologies that can repair ischemic cardiac tissue due to MI, particularly as it is the leading cause 
of death owing to cardiovascular diseases [1, 2]. As cardiomyocytes have low self-renewing 
properties, following MI, their limited ability to regenerate leads to irreversible cardiovascular 
diseases and, eventually, to HF. The most successful treatment for end-stage HF to date is heart 
transplantation, which is a highly invasive procedure limited by the stagnation in heart donors’ 
supply and high immune risks of rejection [1, 6]. Thus, throughout the last decade, myriad tissue 
engineering platforms have developed as alternatives to fabricate systems aimed to repair damaged 
cardiac tissue. Despite progress, the fabrication and clinical application of cardiac constructs that 
are reproducible, biocompatible, and with functional vasculature remains to be established. 
Therefore, there is a clear need for novel techniques to design and fabricate cardiac device systems 
to repair and recover damage to the myocardium and address challenges in current MI treatments. 
 
Among a variety of strategies to engineer cardiac patches for regenerative medicine, 3D 
bioprinting has gained increasing attention as an innovative manufacturing technique presenting a 
wide assortment of advantages [10, 13]. 3D bioprinting allows precise spatial control of 
biomaterials, cells, and biological factors to fabricate functional constructs while manipulating the 
geometry, the integration of nano and microstructures, and direct cellular organization. By these 
means, bioprinting has the potential of designing 3D functional patch devices with biomimetic 
properties resembling those of the native cardiac microenvironment and ECM [14, 15]. Given the 
rising significance of 3D bioprinting for cardiac regeneration, research has focused on 
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investigating a variety of 3D bioprinting approaches: extrusion-based and inkjet-based. The most 
commonly used method is extrusion-based bioprinting, which has been implemented for layer-by-
layer deposition of inks through a syringe-like assembly at constant flows, pressures, and printing 
speeds and is best used for bioinks of low or high viscosities; nevertheless, it is limited by the low 
printing fidelity and resolution [14, 16, 17]. Particularly, Kolesky et al. printed cardiac constructs 
through extrusion under applied pressurized air [16]. However, the authors noted that the desired 
printed filament was dependent upon the alterations in the printing speeds, pressure, nozzle 
diameter, and height from the printing plate. In another study, Hinton et al. suggested that 
extrusion-based bioprinting is preferred when printing with soft materials subject to losing their 
3D structure and when attempting to control the volume being extruded [18]. In contrast, inkjet-
based bioprinting has been used for deposition of inks as droplets. It is preferred solely for bioinks 
with low viscosities and has been shown to have less printing resolution compared to extrusion-
based bioprinting [6, 14, 19].  Moreover, a review by Kyle et al. highlighted the disadvantages of 
inkjet bioprinting focusing on the small volume of droplets in dimensions of pico-liters minimizing 
the ability to print larger, real-size structures [17]. Regardless of the bioprinting method, the 
biomaterials enabling printability and biological cues of patch systems have yet to be specified.    
 
While there is an extensive body of literature precising the selection of biomaterials for tissue 
regeneration, the biocompatibility and fidelity of the biomaterials to mimic the native cardiac ECM 
and microenvironment remain a clinical challenge [20]. Hydrogels are preferred given their 
polymeric, hydrophilic chains and their ability to simulate the biochemical and physical properties 
of the cardiac ECM [21]. Naturally-derived hydrogels, such as collagen or gelatin, are 
biocompatible and biodegradable, but lack the mechanical strength to support the surrounding 
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tissue [21]. Contrarily, synthetically-derived hydrogels, such as poly(ethylene glycol), have high 
mechanical stiffnesses, but present deficiencies in their biocompatibility to the inborn tissue [21]. 
Thus, a blend of natural and synthetic hydrogels would be effective to design cardiac patches with 
regenerative applications [22]. Specifically, the use of gelMA, a hydrogel based on collagen and 
cross-linked methacrylate side groups, has been gaining increasing interest for its hybrid 
properties. Particularly, Bejleri et al. claimed that gelMA is effective for regenerative medicine 
purposes as it has enhanced biomimetic properties and biological cues with the surrounding tissue 
[20]. Furthermore, Yue et al. suggested the facile tunability and effective polymerization using 
UV light as a photo-initiator to provide ideal structure and stiffness for the patch [23]. However, 
the effects of the selected biomaterials on cardiac patch geometry remain unresolved.  
 
Despite progress in the development of 3D bioprinted cardiac patches, one of the most 
significant limitations is construct geometry hindering the diffusion of oxygen and nutrients, which 
enforces restrictions on the construct thickness, biomaterials, and cellular growth. Without oxygen 
and nutrients, cells would not have means of survival and the patch functionality would be 
impacted. In particular, according to Radisic et al., the inclusion of pre-engineered vasculature in 
3D bioprinted patches simulate the capillaries of the body and expand the thickness of clinically 
relevant cardiac patches to ranges between 1 to 5 mm [24]. Therefore, vascularization represents 
a pre-requisite for tissue regeneration. To this end, in recent years, researchers have been 
incorporating vascular networks embedded within the patches using fugitive materials, such as 
sacrificial pluronic bioink that is removed through dilution at low temperatures, leaving hollow 
microvessels for cells to form as a layer of endothelium [25]. Kolesky et al. suggested the 
fabrication of constructs with vascular networks ramifying into branches simulating the capillaries 
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[26]. In their study, the patch was printed with gelMA and the vasculature with pluronic bioink. 
Conversely, the printed vasculature was prone to swelling given the diffusion of water within the 
patch, suggesting that a different geometry and diameter of the embedded networks are required, 
such that it mimics the vasculature in the body ranging from larger to smaller channels and such 
that there is sufficient space between vessels to tolerate any diffusion of water. Withal, dependent 
on the successful oxygen and nutrient diffusion within cardiac constructs is the selection of cells 
to proliferate and remain metabolically active.  
 
Currently, there is conflicting research on the most effective cells that could be used for 3D 
bioprinting of cardiac patch constructs. Multiple cell types can be added to cell-laden bioinks, or 
instead, cell-free bioinks could be utilized. Previous research has shown that HUVECs seeded in 
constructs with endothelial growth medium endothelialize the vascular networks enabling oxygen 
and nutrient diffusion as well as functional metabolic activity of the patch [22, 25-28]. Other 
studies have implemented cells such as mesenchymal stem cells [29], epicardial mesothelial cells 
[30], or induced pluripotent stem cells (iPSCs) [6], which can differentiate and proliferate into 
cardiomyocytes and mimic the native cardiac tissue more effectively. Regardless of the cells 
chosen, studies have demonstrated that cellular proliferation and metabolic activity is augmented 
under conditions, such as rocking or perfusion, which is a result of enhanced cell-to-cell 
communication [26]. However, further studies are required to conclude the effects of culture 
conditions on cell growth and proliferation.  
 
Previous studies have attempted to design and test cardiac patches for myocardium 
regeneration after MI but have been limited by a wide assortment of shortcomings, ranging from 
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limited oxygen and nutrient diffusion to low cellular survival due to the lacking signaling of 
biological cues necessary to promote cell growth and proliferation. Therefore, the aim of this study 
is to investigate the fabrication of perfusable cardiac patch systems with pre-engineered 
vasculature and evaluate in vitro the function of the patch devices through the formation of smooth 
and mature endothelium of the intrinsic vascular network as a potential novel cardiac patch system 
that overcomes current challenges for improved recovery of cardiac function post-MI. Here, the 
cardiac patch is 3D bioprinted with gelMA hydrogel for the construct and sacrificial pluronic 
bioink for the embedded channel network. Overall, the fabrication of 3D bioprinted patches with 
incorporation of vascular networks is reported and the perfusion of cardiac patches and formation 
of hollow microvessels (microcapillaries) is assessed. This study addresses the endothelialization 
of the vasculature in static, dynamic, and perfused culture conditions as well as monitors cellular 
metabolic activity, attachment, and proliferation. Further, the patch geometry and culture 
conditions required for endothelialization of these constructs are studied to determine the efficacy 
of this platform to design constructs that can potentially have regenerative medicine properties to 









  10 
CHAPTER 3 
METHODOLOGY 
The design and fabrication of perfusable 3D bioprinted cardiac patches for cardiac tissue 
regeneration is a result of manipulating the biomaterials to mimic the cardiac microenvironment 
as well as the 3D bioprinting technique to design the precise geometry with vascular networks of 
the cardiac patch devices. Here, cell survival, growth, and the formation of endothelium were 
analyzed by measuring cellular metabolic activity and through qualitative imaging with 
immunostaining to gauge cellular organization and morphology within the channels of the patches.  
 
Bioink Preparation 
To 3D bioprint the cardiac constructs, gelMA bioink at 10% (w/v) was synthesized from 
porcine gelatin type A and methacrylic anhydride as described in previous reports [31, 32]. The 
concentration of the gelMA bioink was chosen based on the high printability and stability of the 
bioink filament during the bioprinting extrusion as well as the high cell viability of gelMA at this 
concentration [33].  To print the intrinsic network of vascular channels, a sacrificial pluronic bioink 
at 38% (w/v) was prepared by dissolving pluronic with phosphate-buffered saline (PBS). As a 
thermosensitive material, pluronic bioink was synthesized at this concentration to exhibit 
controlled printability and shear-thinning of the printed filaments [34].  
 
Design of Cardiac Patch Structures  
The 3D model of the cardiac patch with perfusable vascular channels was created as a 
computer-aided design (CAD) model using Autodesk Fusion360® software (Autodesk, Inc., USA). 
The cardiac patch geometry featured a disk structure with dimensions of 15 mm in diameter and 3 
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mm in thickness (Figure 1). The modeled vascular network intrinsic to the disk-shaped construct 
followed a 1-2-4-2-1 ramification structure beginning at a microvessel diameter of 1.4 mm, which 
bifurcated in two channels of 1 mm in diameter, and then ramified once again in two branches of 
0.7 mm in diameter to mimic the ramification of vessels and capillaries within the cardiac system. 
The patch has a single inlet and a single outlet to provide an interface between the scaffold and the 
perfusion system. After designing the construct, the CAD model of the cardiac patches was 
converted to the standard stereolithography (STL) format file for printing.  
 
 
Figure 1. Design of the Cardiac Patch Device. 3D design of the disc-shaped cardiac patch with pre-
engineered vascular networks. Top perspective of the cardiac patch (A). Lateral perspective of the cardiac 
patch (B). The cardiac construct is 15 mm in diameter and 3 mm in thickness. Following a 1-2-4-2-1 
structure, the network of vascular channels within the disc-shaped construct has a diameter of 1.4 mm, 1 
mm, and 0.7 mm, respectively, with a single inlet and outlet.  
 
3D Bioprinting of Cardiac Patches 
A multi-extruder 3D bioprinter with three printheads (BioX, CELLINK) was implemented to 
3D bioprint the constructs. The cardiac patches were printed using 10% (w/v) gelMA mixed with 
0.5% (w/v) Irgacure photoinitiator, which allows absorbance of the UV light for photo-
crosslinking. The microvessels were printed with 38% (w/v) sacrificial pluronic bioink, which 
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degrades at low temperatures. A temperature-controlled pneumatic extrusion-based printhead was 
employed to print with gelMA because of its thermo-reversible properties. A standard pneumatic 
extrusion-based printhead was used to print with pluronic with respective printing parameters 
(Table 1). Subsequently, the bioprinted constructs were crosslinked with UV light at 2.5 mW/cm2 
for 45 seconds on each side of the patch to ensure adequate and uniform mechanical stiffness to 
promote cell growth. The cardiac patches were then incubated in PBS at 4°C for 4 hours for the 
pluronic to degrade and generate hollow microvessels within the gelMA patch.  
 
Table 1. Printing Parameters for BioX, CELLINK 3D Bioprinter. 
 
 
Cell Culture of Printed Cardiac Patches 
Cell seeding of the printed patches was performed manually in vitro to assess the cellular 
growth and metabolic activity of the cultured cells, with the goal of creating a uniform and 
continuous endothelium covering onto the channels. Prior to cell seeding, the luminal surface of 
the channels was coated with fibrin hydrogel. For this purpose, the fibrin coating was done with 
fibrinogen treatment at 1 mg/ml for 2 hours followed by thrombin enzyme at 2 U/ml for 30 minutes 
at 37°C. Subsequently, we prepared 60 µl of solution consisting of HUVECs suspended in the 
endothelial growth media (VEGF LS-1020) at a density of 16 million cells/ml. Cell suspension 
was injected through the inlet of the printed construct into the fibrin-coated channels and incubated 
at 37°C for 7 days in static condition to promote cell attachment and growth. After the 7-day 
 Parameter  Dimensions for GelMA Printing  Dimensions for Pluronic Printing 
 Nozzle Gauge  27 gauge  27 gauge
 Temperature  23°C  22.5°C
 Speed  6 mm/s  4 mm/s
 Pressure  35 kPa  80 kPa
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culture in static, the cellular constructs were introduced to one of the following culture conditions: 
static, dynamic (rocking), and perfusion. 
 
Perfusion of Printed Cardiac Patches 
The bioprinted cardiac patches were inserted into a custom designed 3D printed chamber, 
which was connected to a peristaltic pump bioreactor system for perfusion to evaluate the 
formation of fully patent channels and test the perfusion culture conditions on the viability and 
growth of HUVECs in the microchannels (Figure 2). A 3D printed chamber was used to house 
the cardiac patch. Tubing with an inner diameter of 1.52 mm served to connect the bioprinted 
housing to a reservoir of HUVEC media. The bioreactor system was maintained in an incubator at 
37°C to ensure adequate temperature for cellular growth. During a one-week perfusion culture 
period, endothelial growth media was flown through the HUVEC-seeded vascular channels at a 
flow rate of 111 µl/min to simulate the blood flow in small vessels.  
 
Figure 2. Bioreactor Perfusion Pump Setup. A setup of the perfusion bioreactor system implemented to 
pump HUVEC media through the vascular channels embedded within the cardiac patches. The cardiac 
constructs were inserted into customized 3D printed chambers, shown to the right. The peristaltic pump 
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bioreactor, shown to the left, was connected to the 3D printed chambers, which housed the 3D bioprinted 
cardiac patches, through tubing with an inner diameter of 1.52 mm. The HUVEC media was flown through 
the HUVEC-seeded vascular networks at a flow rate of 111 µl/min. 
 
Analyzing Cell Viability and Proliferation 
The cardiac constructs were tested with a noninvasive AlamarBlue assay throughout a two-
week culture period. The percentage of AlamarBlue reduction was used to quantitatively analyze 
the changes in cellular metabolic activity levels, as a measure of cell viability and growth [35, 36]. 
Constructs were incubated with the AlamarBlue assay (AlamarBlue® Cell Viability Reagent, 
BioRad) at 37°C for 4 hours in static culture conditions. The cardiac constructs in dynamic 
(rocking) culture conditions were maintained on a rocker at 60 revolutions/min for the 4 hours of 
AlamarBlue incubation time. For the perfused patches, 10% AlamarBlue solution was added to 
the media reservoir and was run for 4 hours. To measure the percentage of reduced reagents, the 
media was sampled from each construct after 4 hours and the absorbance of the solution was 
measured at wavelengths of 550 nm and 660 nm via a microplate reader (BioTekTM SynergyTM 2 
Multi-Mode Microplate Reader). This viability and metabolic activity assay was performed at days 
3, 7, 10, and 14 during the in vitro culture. 
 
Immunohistochemistry and Confocal Microscopy 
At days 7 and 14 of the culture period, the cardiac patches were fixed in 4% paraformaldehyde 
and stained to assess cell morphology and organization within the vascular channels. Constructs 
were stained against 4′,6-diamidino-2-phenylindole (DAPI) as a cell nucleus marker, wheat germ 
agglutinin (WGA) to stain cell membrane, and CD31 as an endothelial cell marker to gauge the 
organization and morphology of cells. The stained constructs were then imaged using a confocal 
laser scanning microscope (Olympus FV1000) to qualitatively assess the formation of endothelium 
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All results presented are expressed as mean ±	standard error of the mean (SEM). A one-way 
ANOVA was used to determine statistically significant differences in AlamarBlue reduction, 
which positively correlates to cellular metabolic activity, within the culture conditions of cardiac 
patches at day 3, 7, 10, and 14, respectively. Consecutively, a post-hoc Tukey-Kramer was 
performed for multiple comparisons between culture conditions. Particularly, a p-value < 0.05 was 
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CHAPTER 4 
RESULTS 
3D Bioprinted Cardiac Patches 
The CAD model of the cardiac patches was successfully 3D bioprinted with 10% (w/v) gelMA 
hydrogel and the channel network was effectively bioprinted with 38% (w/v) sacrificial pluronic 
bioink (Figure 3). Furthermore, perfusing the microvessels with endothelial growth media 
demonstrated that the pluronic bioink successfully degraded at 4°C and thereby generated fully 
patent channels within the hydrogel constructs.  
 
 
Figure 3. Bioprinted Cardiac Patches. The CAD model of the cardiac patch system successfully 3D 
bioprinted using gelMA with vascular networks printed utilizing pluronic. Top perspective of the cardiac 
patch (A). Lateral perspective of the cardiac patch (B). 
 
Endothelial Cell Viability and Growth in Cardiac Patches 
To assess the biocompatibility of the bioinks used for the development of the cardiac patches 
and to assess the HUVEC culture conditions, the percentage of AlamarBlue reduction was 
determined at days 3, 7, 10, and 14 of static, dynamic (rocking), and perfusion culture conditions 
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(Figure 4). AlamarBlue results indicated that HUVECs remained viable and metabolically active 
throughout the 14-day culture in static, rocking, and perfusion conditions. In addition, day 7 
resulted in statistically the greatest levels of AlamarBlue reduction across all timepoints. 
Particularly, in rocking and perfusion, the AlamarBlue reduction was measured at 20.83 ±	0.99 % 
and 22.85 ±	0.24 %, respectively. In contrast, in static culture conditions, the changes in cellular 
metabolic activity were greatest for day 14 (22.83 ± 1.37 %) with a non-significant difference 
compared to day 7 (22.61 ±	1.52 %).  
 
Statistically significant differences in AlamarBlue reduction were determined among culture 
conditions within 3D bioprinted cardiac patches at days 3, 7, 10, and 14, respectively. At day 3 
and day 7, no significant differences were found in AlamarBlue reduction for patches in static, 
rocking, or perfusion conditions. At day 10 and day 14, there was no significant difference in 
AlamarBlue reduction between static and rocking conditions. However, there was a statistically 
significant decrease (p-value < 0.0001) in cell viability between cardiac patches in static and 
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Figure 4. Characterization of Endothelial Cell Viability and Growth in 3D Bioprinted Cardiac 
Patches. Cellular metabolic activity of HUVECs seeding in the vascular networks of the 3D bioprinted 
cardiac patches measured by the percentage of AlamarBlue reduction throughout a 14-day in vitro culture 
in static, dynamic (rocking), and perfusion conditions (n = 4 per group). Results reported as mean ±	SEM. 
* p-value < 0.05, ** p-value < 0.01, **** p-value < 0.0001. 
 
Endothelialization of the Vascular Channels 
The organization and morphology of HUVECs cultured within the vasculature was assessed 
by confocal microscopy. As alamarBlue assay results showed greatest cell viability and growth for 
cardiac patches in the static culture, in comparison to constructs in rocking or perfusion, 
immunofluorescence imaging was performed on static cardiac constructs. Furthermore, as day 7 
showed the greatest cellular metabolic activity consistent among all conditions, the confocal 
imaging was performed on constructs at day 7. For the cardiac patches stained against DAPI, 
WGA, and CD31, confocal microscopy imaging of the channels at bifurcations 1, 2, and 4 
indicated effective attachment and proliferation of HUVECs within the walls of the vascular 
networks (Figure 5). GFP staining demonstrated viable HUVECs lined up on the channel walls of 
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the cardiac patch (Figure 6). In addition, HUVEC nuclei staining (DAPI) demonstrated the 
formation of layers of endothelium on the lumen area of the vasculature; however, the coverage of 
HUVECs was not uniform within the walls of the channels (Figure 7). This could be attributed, at 
least partly, to the gravitational forces exerted onto the seeded HUVECs, which highlights the need 
for future studies to improve cellularization of printed constructs (e.g., flipping the constructs post 
seeding to achieve a more uniform cell distribution).   
 
 
Figure 5. Characterization of HUVEC Organization and Morphology in the Microchannels of the 3D 
Bioprinted Cardiac Patches. Cardiac patches with perfusable vascular networks seeded with HUVECs 
were stained against DAPI (blue), WGA (red), and CD31 (green). The channels of the cardiac patches 
organized in a 1-2-4-2-1 structure were visualized through confocal microscopy. Immunofluorescence 
imaging of channel bifurcation 1 (A), 2 (B), 4 (C) in static culture conditions at day 7. Scale bars: 200 µm.  
 
 
Figure 6. HUVEC Attachment in the Microchannels of the 3D Bioprinted Cardiac Patches. 
Representative GFP (green) images of live HUVECs attached to the walls of the microchannels at 
bifurcation 1 (A), 2 (B), 4 (C) of the bioprinted cardiac constructs in static conditions at day 7. Scale bars: 
500 µm.  
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Figure 7. Coverage of HUVECs in the Microchannels of the 3D Bioprinted Cardiac Patches. 
Immunofluorescence imaging staining against DAPI (blue) to gauge the coverage of HUVEC nuclei within 
the lumen area of the vascular networks to characterize the endothelialization of the microchannels of the 
cardiac patches in static conditions at day 7. Imaging of channel bifurcations 1 (A, D), 2 (B, E), and 4 (C, 
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CHAPTER 5  
DISCUSSION 
Bioengineered cardiac patch devices have been developed over the past years and have shown 
to be effective in regenerating cardiac tissue after MI. Particularly, cardiac constructs made of 
ECM with seeded cells have suggested to be effective in repairing cardiac tissue and promoting 
cardiomyocytes after an ischemic injury. Nonetheless, the utilization and translation of these 
scaffolds to clinical settings have been limited due to the lack of biological cues to promote tissue 
regeneration, poor vascularization, and consequently, reduced cell survival and functionality. To 
overcome these shortcomings, we investigated the fabrication of a 3D bioprinted cardiac patch 
system with perfusable vasculature and applied this platform in vitro to study the viability and 
growth of HUVECs within the microchannels of the patches. Our results demonstrate high-fidelity 
bioprinting of the cardiac patches utilizing gelMA bioink. Intrinsic microchannel networks, printed 
with sacrificial pluronic bioink, established stable and perfusable vascular mimics. The 3D design 
supported the attachment and metabolic activity of HUVECs seeded within the channels and 
exhibited in vitro a functional vasculature with mature endothelium. Thereby, these results indicate 
that the cardiac patch design is an effective vehicle for cell survival and proliferation, which overall 
leads to a better 3D model to repair and regenerate in vitro cardiac tissue after MI.   
 
Design and Material Characterization of Bioprinted Cardiac Patches 
In comparison to other strategies to generate 3D scaffolds, such as hydrogel molding (casting), 
electrospinning, and 3D spheroid systems, bioprinting offers unique advantages in fabricating 
organized 3D patches with precise architectural and spatial control of the geometry [10, 13]. 
Therefore, over the past years, there has been a rising interest in 3D bioprinting as it has been 
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reported to generate anatomically and physiologically complex constructs mimicking native tissue 
while accurately printing with multiple materials and cells [16]. However, despite progress in 3D 
bioprinting for cardiac regenerative medicine, the designs of the constructs thus far have shown to 
have limited bioactivity and restricted oxygen and nutrient diffusion resulting in scaffolds that do 
not support functional activities of cardiomyocytes nor promote cardiac tissue regeneration. 
Consequently, this study utilized 3D bioprinting to address current challenges in cardiac patch 
designs. Here, clinically thick disk-shaped constructs were successfully printed using gelMA with 
pre-engineered vascular networks following a 1-2-4-2-1 structure printed with pluronic using a 
multi-extruder bioprinter (Figure 3). The embedded vasculature was precisely printed which 
allowed the designed cardiac patch channels to be comparable to small arteries or arterioles. The 
geometry control offered by extrusion-based bioprinting at controlled nozzle gauge, printing 
speeds, temperature, pressure, and nozzle-plate distance showed effective printing of the cardiac 
patch device (Table 1).  
  
However, crucial to the fabrication of 3D bioprinted cardiac scaffolds with intrinsic 
vasculature is the design of cardiac patches that are biocompatible and photo-crosslinkable with 
facile tunability and high printing fidelity. Therefore, gelMA hydrogel was used to print the cardiac 
patch devices as it has been shown to have superior tunable physicochemical characteristics and 
biocompatibility. Nevertheless, despite the great potential of gelMA as a hydrogel, the 
concentration of gelMA that offers high printing fidelity and mechanical stiffness while sustaining 
biological cues and promoting cellular survival remains a challenge. Prior studies have shown that 
gelMA at concentrations greater than 15% (w/v) have strong shape fidelity but low cellular 
survival [37] while gelMA at less than 5% (w/v) has shown high cell viability but low structural 
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printability [38]. Thus, printing with gelMA at 10% (w/v) could allow high-fidelity printing with 
high cell bioactivity. Likewise, 38% (w/v) pluronic bioink, a fugitive thermosensitive material 
which degrades at low temperatures, was used to print the vascular networks of the patch devices. 
The sacrificial pluronic once degraded at 4°C could generate hollow microchannels in the patch. 
Effectively, from this study, the optimal shape fidelity of the gelMA and pluronic bioinks after 
bioprinting the cardiac patch systems demonstrated that they could be used to print in 3D disk-
shaped constructs and complex small vessels similar in size to capillaries. Particularly, after 
perfusion of the vascular networks at a physiological flow rate, we demonstrated that the cardiac 
patch maintained the integrity of fully patent channels, which once again demonstrates the 
adequate printability and mechanical properties of gelMA and pluronic to design perfusable 3D 
cardiac constructs.  
 
Evaluation of Cellular Growth and Viability In Vitro in Bioprinted Cardiac Patches 
To assess effectiveness of the designed 3D structure of the cardiac patch and the selection of 
biomaterials, the function of printed patches with perfusable vasculature was evaluated in vitro in 
static, dynamic (rocking), and perfusion culture conditions. The channels of the constructs were 
seeded with HUVECs and cultured throughout a two-week period to form smooth and mature 
endothelium. AlamarBlue assay was run at days 3, 7, 10, and 14 to measure percentage of 
AlamarBlue reduction, which positively correlates to changes in cellular metabolic activity levels, 
as a measure of cell viability and growth (Figure 4). Interestingly, in contrast to previous research, 
no significant differences were found in cell viability and growth across all timepoints between 
static and dynamic conditions. This could be attributed to the brief period to which the cardiac 
patches were subjected to rocking and the lack of fluidic flow changing directions within the 
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channels of the patch [39]. In addition, cardiac patches cultured in static and rocking conditions 
exhibited a growth trend which increased throughout most timepoints. On the other hand, although 
perfused cardiac patches exhibited a growth tendency not significantly different than constructs in 
static and dynamic conditions at day 3 and day 7, we found significant decrease in cells’ metabolic 
activity after day 7. This decreasing trend in perfused patches could be accredited due to 
unidirectional flow of HUVEC media causing increased shear stresses on the channel walls, which 
could reduce the metabolic activity of cells [40]. Nonetheless, further testing must be conducted 
to conclude the growth trends in static, dynamic, and perfused constructs in a 14-day period and 
analyze which culture condition is most effective on cellular growth and viability.  
 
Thus far, these results suggest that cardiac patches cultured in static, or dynamic (rocking) 
conditions would be an optimal group to support cell growth and metabolic activity.  Furthermore, 
for cardiac patches in static and rocking, the significant increase among most timepoints in cellular 
metabolic activity indicate that, at a prolonged culture period, these cardiac patch systems could 
effectively sustain HUVEC growth and proliferation. Likewise, the non-significant decrease at day 
10 may be indicative of a slower metabolism rather than the complete lack of growth and metabolic 
activity. In contrast, the decrease in metabolic activity at day 10 and forwards in perfused cardiac 
patches can be attributed to the limited diffusion of nutrients and oxygen throughout the patch. 
Given that static and dynamic cardiac constructs presented greatest cellular metabolic activity with 
a growth trend consistent between both groups, indifferently, the static patches were selected for 
confocal imaging. In addition, as the greatest cellular metabolic activity was observed at day 7, 
imaging was performed at this day to qualitatively observe HUVEC organization and morphology.  
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Characterization of Cellular Organization and Morphology in Vascular Networks of 
Bioprinted Cardiac Patches 
The images acquired from confocal microscopy are a qualitative representation of the 
proliferation and attachment of HUVECs to the channel walls (Figure 5). In static conditions, the 
channels of the cardiac patches showed effective attachment and proliferation in channels 1, 2, and 
4. Particularly, HUVECs are shown to form smooth, uniform, and relatively mature endothelium 
in the interior of the vascular network. These findings suggest that HUVECs can successfully 
proliferate and grow within the vascular networks of this cardiac patch system. Significantly, these 
results can be attributed to the effective oxygen and nutrient diffusion throughout the clinically 
thick construct offered by the embedded vascular channels and their dimensions comparable to the 
sizes of arterioles in the body [24]. Additionally, GFP imaging of the microchannels of constructs 
qualitatively suggest the proliferative action of HUVECs within the walls of the pre-engineered 
vasculature (Figure 6). These results suggest that the CAD model, biomaterials, and culture 
conditions were adequate to maintain living cells within the channel walls. Moreover, confocal 
images of the staining of the cell nucleus show the channels have been cellularized as well as the 
HUVEC attachment and formation of a uniform endothelium throughout the lumen of the vascular 
channels (Figure 7).  However, the attachment of HUVECs on the channel walls does not represent 
a uniform coverage of the lumen of the vasculature, which could be accredited to the low stiffness 
of the construct that hinders strong binding of cells to the channel surface at the given flow rate. 
Further optimization of flow rate as well as channel wall stiffness should be conducted in future 
studies to translate the results into an improved endothelialization of the channel walls.  
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Overall, in comparison to the formation of endothelium within channels 1, 2, and 4, 
immunofluorescence imaging qualitatively shows greater proliferation and attachment of 
HUVECs to the walls in channel 1 but decreases in channel 2 and 4, respectively, which can be 
ascribed to the smaller diameters of these channels. Further optimizations of the channel 4 diameter 
should be elaborated on to further understand their impact on cellular survival and metabolic 
activity. In general, these findings from confocal microscopy suggest the biocompatibility and 
suitability of gelMA prints to sustain biological cues and mimic the ECM. Furthermore, the results 
propose the effectiveness of the intrinsic vasculature to allow for oxygen and nutrient diffusion 
within the microchannels and throughout the 3 mm thickness of the cardiac construct.  
 
In this study, we demonstrate the successful bioprinting of gelMA cardiac constructs with 
perfusable microchannels. Effectively, in vitro, HUVECs seeded throughout a 14-day culture were 
metabolically active and formed a mature smooth endothelium within the walls of the vascular 
network, which suggest the cardiac patch design and culture to be effective for HUVEC survival 
and proliferation. Moving forward, this cardiac patch system with perfusable vascular networks 
can be applied in vitro to create improved 3D models to regenerate cardiac tissue after an 
irreversible ischemic event and apply them in vivo to study their regenerative capacity.  
 
Future Work  
For future works, these cardiac patch systems can be 3D bioprinted using gelMA containing 
iPSCs differentiated into cardiomyocytes and endothelial cells. This would allow us to evaluate 
the microenvironment of cardiac scaffolds to support cardiomyocyte growth and function, and 
endothelialization of the vascular networks. Furthermore, future studies can apply the bioprinted 
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cardiac patches in vitro and in vivo to study the response of cardiomyocytes to epicardial paracrine 
peptides, such as the pro-proliferative follistatin-like 1 (FSTL 1) peptide, which has been reported 
to promote cardiomyocyte proliferation and regeneration of the ischemic myocardium. Ultimately, 
multiple iterations of the cardiac patch systems fabricated in this work can be developed to 
investigate the most effective, biocompatible patch devices with functional endothelialized pre-





















In this study, we investigated the fabrication of a 3D bioprinted cardiac patch device 
incorporated with perfusable microchannels and evaluated in vitro the endothelial cell growth to 
create fully endothelialized functional vascular networks within the patch. The results from this 
study suggest that the 3D model of the cardiac patch system with perfusable vasculature can be 
successfully bioprinted using soft gelMA hydrogel bioinks, while printing the channels with 
sacrificial pluronic. Furthermore, the cardiac patches designed showed enhanced 
endothelialization of the embedded channels and high cellular metabolic activity throughout the 
two-week culture periods. However, further optimization of the perfusion system, channel wall 
stiffnesses, and culture conditions should be conducted in the future. In addition, future studies 
can include bioprinting the cardiac patches with iPSCs differentiated into cardiomyocytes and 
endothelial cells or the incorporation of cardiogenic paracrine factors to promote greater 
cardiomyocyte proliferation and regeneration of the ischemic myocardium. Overall, this novel 
platform provides an alternative approach for 3D bioprinting cardiac patch devices with perfusable 
vascular networks which can be implemented both in vitro and in vivo to address current challenges 
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